MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients
Open Access
- 15 November 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Medicine
- Vol. 14 (1), 1-9
- https://doi.org/10.1186/s12916-016-0708-1
Abstract
Multiple Endocrine Neoplasia type 1 (MEN1) is diagnosed when two out of the three primary MEN1-associated endocrine tumors occur in a patient. Up to 10–30 % of those patients have no mutation in the MEN1 gene. It is unclear if the phenotype and course of the disease of mutation-negative patients is comparable with mutation-positive patients and if these patients have true MEN1. The present study aims to describe and compare the clinical course of MEN1 mutation-negative patients with two out of the three main MEN1 manifestations and mutation-positive patients during long-term follow-up. This is a cohort study performed using the Dutch MEN1 database, including > 90 % of the Dutch MEN1 population. A total of 293 (90.7 %) mutation-positive and 30 (9.3 %) mutation-negative MEN1 patients were included. Median age of developing the first main MEN1 manifestation was higher in mutation-negative patients (46 vs. 33 years) (P = 0.007). Mutation-negative patients did not develop a third main MEN1 manifestation in the course of follow-up compared to 48.3 % of mutation-positive patients (P < 0.001). Median survival in mutation-positive patients was estimated at 73.0 years (95 % CI, 69.5–76.5) compared to 87.0 years (95 % CI not available) in mutation-negative patients (P = 0.001). Mutation-positive and mutation-negative MEN1 patients have a different phenotype and clinical course. Mutation-negative patients develop MEN1 manifestations at higher age and have a life expectancy comparable with the general population. The apparent differences in clinical course suggest that MEN1 mutation-negative patients do not have true MEN1, but another MEN1-like syndrome or sporadic co-incidence of two neuro-endocrine tumors.Funding Information
- Ipsen pharmaceutical BV
- Comprehensive Cancer Center Netherlands
This publication has 35 references indexed in Scilit:
- Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4)Molecular and Cellular Endocrinology, 2014
- Gender-related differences in MEN1 lesion occurrence and diagnosis: a cohort study of 734 cases from the Groupe d'étude des Tumeurs EndocrinesActa Endocrinologica, 2011
- Rare Germline Mutations in Cyclin-Dependent Kinase Inhibitor Genes in Multiple Endocrine Neoplasia Type 1 and Related StatesJournal of Clinical Endocrinology & Metabolism, 2009
- Germline mutations in theCDKN1Bgene encoding p27Kip1are a rare cause of multiple endocrine neoplasia type 1Clinical Endocrinology, 2009
- Developing Effective Screening Strategies in Multiple Endocrine Neoplasia Type 1 (MEN 1) on the Basis of Clinical and Sequencing Data of German Patients with MEN 1Experimental and Clinical Endocrinology & Diabetes, 2007
- Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1‐associated pancreatic endocrine tumoursClinical Endocrinology, 2007
- Age‐related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriersClinical Endocrinology, 2007
- Germ-line mutations in p27
Kip1
cause a multiple endocrine neoplasia syndrome in rats and humansProceedings of the National Academy of Sciences of the United States of America, 2006
- Mutational and gross deletion study of the MEN1 gene and correlation with clinical features in Spanish patientsJournal of Medical Genetics, 2003
- Clinical studies of multiple endocrine neoplasia type 1 (MEN1)QJM: An International Journal of Medicine, 1996